DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 7.64

Change

+0.03 (+0.39)%

Market Cap

USD 0.17B

Volume

0.74M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.60 (+0.61%)

USD 18.39B
IVV:AU iShares Core S&P 500 AUD

+0.34 (+0.61%)

USD 11.33B
VGS:AU Vanguard MSCI International Sh..

+0.89 (+0.70%)

USD 10.39B
QUAL:AU VanEck Vectors MSCI World ex A..

+0.24 (+0.45%)

USD 7.35B
IOZ:AU Ishares Core S&P/Asx 200

+0.17 (+0.53%)

USD 6.40B
VTS:AU Vanguard US Total Market Share..

+2.46 (+0.60%)

USD 5.71B
STW:AU SPDR® S&P/ASX 200 Fund

+0.48 (+0.67%)

USD 5.54B
NDQ:AU Betashares Nasdaq 100

+0.35 (+0.81%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

-0.04 (-0.11%)

USD 4.86B
A200:AU BetaShares Australia 200

+0.81 (+0.61%)

USD 4.72B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.80% 50% F 56% F
Dividend Return 0.35% 10% F 6% D-
Total Return -2.45% 44% F 54% F
Trailing 12 Months  
Capital Gain -9.16% 10% F 47% F
Dividend Return 2.98% 41% F 34% F
Total Return -6.18% 10% F 47% F
Trailing 5 Years  
Capital Gain 18.63% 34% F 56% F
Dividend Return 11.36% 25% F 20% F
Total Return 30.00% 30% F 53% F
Average Annual (5 Year Horizon)  
Capital Gain 5.89% 61% D- 55% F
Dividend Return 7.75% 61% D- 55% F
Total Return 1.86% 55% F 38% F
Risk Return Profile  
Volatility (Standard Deviation) 8.24% 66% D+ 92% A
Risk Adjusted Return 94.13% 86% B+ 94% A
Market Capitalization 0.17B 32% F 65% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.